268 related articles for article (PubMed ID: 8971431)
1. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.
Mandema JW; Kaiko RF; Oshlack B; Reder RF; Stanski DR
Br J Clin Pharmacol; 1996 Dec; 42(6):747-56. PubMed ID: 8971431
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers.
Ladebo L; Foster DJR; Abuhelwa AY; Upton RN; Kongstad KT; Drewes AM; Christrup LL; Olesen AE
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):263-276. PubMed ID: 31597014
[TBL] [Abstract][Full Text] [Related]
3. Steady-state bioavailability of controlled-release oxycodone in normal subjects.
Reder RF; Oshlack B; Miotto JB; Benziger DD; Kaiko RF
Clin Ther; 1996; 18(1):95-105. PubMed ID: 8851456
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.
Webster LR; Bath B; Medve RA; Marmon T; Stoddard GJ
Pain Med; 2012 Jun; 13(6):790-801. PubMed ID: 22568663
[TBL] [Abstract][Full Text] [Related]
5. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.
Kaplan R; Parris WC; Citron ML; Zhukovsky D; Reder RF; Buckley BJ; Kaiko RF
J Clin Oncol; 1998 Oct; 16(10):3230-7. PubMed ID: 9779696
[TBL] [Abstract][Full Text] [Related]
6. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.
Scheidel B; Maritz MA; Gschwind YJ; Steigerwald K; Guth V; Kovacs P; Rey H
Int J Clin Pharmacol Ther; 2017 Nov; 55(11):881-890. PubMed ID: 28933336
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.
Benziger DP; Kaiko RF; Miotto JB; Fitzmartin RD; Reder RF; Chasin M
J Pharm Sci; 1996 Apr; 85(4):407-10. PubMed ID: 8901078
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients.
Stambaugh JE; Reder RF; Stambaugh MD; Stambaugh H; Davis M
J Clin Pharmacol; 2001 May; 41(5):500-6. PubMed ID: 11361046
[TBL] [Abstract][Full Text] [Related]
11. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
[TBL] [Abstract][Full Text] [Related]
12. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
Franke RM; Morton T; Devarakonda K
Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
[TBL] [Abstract][Full Text] [Related]
13. Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets.
Kim JY; Lee SH; Park CW; Rhee YS; Kim DW; Park J; Lee M; Seo JW; Park ES
Drug Des Devel Ther; 2015; 9():695-706. PubMed ID: 25678774
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.
Webster LR; Iverson M; Pantaleon C; Smith MD; Kinzler ER; Aigner S
Pain Med; 2019 Apr; 20(4):747-757. PubMed ID: 29608768
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone.
Benziger DP; Miotto J; Grandy RP; Thomas GB; Swanton RE; Fitzmartin RD
J Pain Symptom Manage; 1997 Feb; 13(2):75-82. PubMed ID: 9095564
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist.
Toyama K; Furuie H; Kuroda K; Ishizuka H
Drugs R D; 2017 Sep; 17(3):363-370. PubMed ID: 28516342
[TBL] [Abstract][Full Text] [Related]
17. Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets.
Morton T; Franke R; Devarakonda K
Pain Pract; 2016 Jul; 16(6):730-6. PubMed ID: 26218586
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
19. Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain.
Citron ML; Kaplan R; Parris WC; Croghan MK; Herbst LH; Rosenbluth RJ; Reder RF; Slagle NS; Buckley BJ; Kaiko RF
Cancer Invest; 1998; 16(8):562-71. PubMed ID: 9844616
[TBL] [Abstract][Full Text] [Related]
20. Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users.
Raofi S; Kinjo M; Sun D; Li Z; Boyce H; Natarajan K; Frost M; Zhao L; Luke M; Lionberger R; Kelsh D; Kim MJ
Clin Transl Sci; 2021 Sep; 14(5):1977-1987. PubMed ID: 33982418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
